title: Neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer: which patients benefit?
abstract: Level I evidence supports neoadjuvant chemotherapy in the treatment of advanced bladder cancer. For the most benefit, it is suggested that neoadjuvant chemotherapy be restricted to patients with clinical T3 disease and/or clinical N+ disease.
authors.affiliation: Department of Urology, Heinrich-Heine-University, Düsseldorf, Germany.
authors.forename: Günter
authors.initials: G
authors.lastname: Niegisch
authors.forename: Anja
authors.initials: A
authors.lastname: Lorch
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Droller
authors.forename: Hugh J
authors.initials: HJ
authors.lastname: Lavery
authors.forename: Kristian D
authors.initials: KD
authors.lastname: Stensland
authors.forename: Peter
authors.initials: P
authors.lastname: Albers
mesh_terms: D017024:Chemotherapy, Adjuvant; D015653:Cystectomy / Q000009:adverse effects / Q000401:mortality / Q000592:standards; D019317:Evidence-Based Medicine; D006801:Humans; D020360:Neoadjuvant Therapy / Q000009:adverse effects / Q000401:mortality / Q000592:standards; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D018579:Patient Selection; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*